We made the next important step on the way to the registration of our drug candidates in the European Medicines Agency.
The next phase of research has started for our two medicinal products: BCX-CM-J – a drug candidate for the treatment of degenerative joint lesions and BCX-CM-AD – a drug candidate for the treatment of atopic dermatitis. It’s the safety phase called TAS (Target Animal Safety), in which the safety of the route of drag administration is tested. We sent a product batch for testing in the certified CRO (Clinical Research Organisation). The series has been manufactured in accordance with the GMP (Good Manufacturing Practice) pharmaceutical standard.
This is an important moment for us – if we confirm the safety of the route of administration of our drug candidates, we will be able to proceed to the next stage – to the tests of their effectiveness in a clinical field trial executed on clinical patients.